0000000000200947

AUTHOR

Berna Yalınçetin

showing 6 related works from this author

White Noise Speech Illusions: A Trait-Dependent Risk Marker for Psychotic Disorder?

2019

Supported by the European Community’s Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI)

SYMPTOMSCommunity Assessment of Psychic ExperiencesPsychotic disorder0302 clinical medicinecognitive abilitylcsh:PsychiatrySCHIZOPHRENIASalut mentalOriginal Researchmedia_commonPsychiatryCognitive abilityCognition16. Peace & justiceCHILDHOOD TRAUMAPsychiatry and Mental healthSchizophreniaRELIABILITYTraitHALLUCINATIONSClinical psychologyInfàncialcsh:RC435-571media_common.quotation_subjectIllusionQUESTIONNAIREPsicosiLife events03 medical and health scienceschildhood adversityTHREATENING EXPERIENCESmedicinePsiquiatriaSiblingVALIDITYAssociation (psychology)White noise speech illusionsENVIRONMENTwhite noise speech illusionsbusiness.industrySHORT-FORMPsychosesOdds ratiopsychotic disordermedicine.diseaseChildhoodConfidence interval030227 psychiatrylife eventsTrastorns de la parlaChildhood adversitybusiness030217 neurology & neurosurgery
researchProduct

Examining the independent and joint effects of genomic and exposomic liabilities for schizophrenia across the psychosis spectrum

2020

The EUGEI project was supported by the European Community’s Seventh Framework Program under grant agreement no. HEALTH-F2-2009-241909 (Project EU-GEI). Dr O’Donovan is supported by MRC programme grant (G08005009) and an MRC Centre grant (MR/ L010305/1). Dr Rutten was funded by a VIDI award number 91718336 from the Netherlands Scientific Organisation. Drs Guloksuz and van Os are supported by the Ophelia research project, ZonMw grant number: 636340001. Dr Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, PI19/024); CIBERSAM; Madrid Regional Government (B2017/BMD-3740, AGES-CM-2); Fundación Familia Alonso and Fundac…

AdultMaleExposomePsychosisMultifactorial InheritanceEpidemiologyBIRTHSchizotypystructured interviewGENE-ENVIRONMENTPopulationschizotypypopulationEnvironment03 medical and health sciences0302 clinical medicineMedicineHumansSpectrum disorderGenetic Predisposition to DiseasegeneticspsychosiseducationMETAANALYSISvalidationRISKeducation.field_of_studychildhood traumareliabilitybusiness.industryPublic Health Environmental and Occupational HealthAbsolute risk reductionassociationRegression analysisGenomicsmedicine.disease3. Good health030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaFemaleGene-Environment InteractionSchizophrenic PsychologyOriginal Articlebusiness030217 neurology & neurosurgeryClinical psychologyEpidemiology and Psychiatric Sciences
researchProduct

A replication study of JTC bias, genetic liability for psychosis and delusional ideation

2022

The EUGEI project was supported by the European Community's Seventh Framework Program under grant agreement No. HEALTH-F2-2009-241909 (Project EU-GEI). Dr O'Donovan is supported by MRC programme grant (G08005009) and an MRC Centre grant (MR/L010305/1)

PsychosisfamilyHallucinationsCONVICTIONDecision Makingneuropsychology03 medical and health sciences0302 clinical medicineCognitionBiasmedicineHumansSpectrum disorderpsychosisSiblingVALIDITYAssociation (psychology)jumping to conclusionsApplied PsychologyNeuropsychologyCognitionmedicine.disease030227 psychiatryPsychiatry and Mental healthCONTINUUMPsychotic DisordersRelative riskJumping to conclusionsCONCLUSIONSRELIABILITYSchizophreniadelusionsreasoningPsychology030217 neurology & neurosurgeryClinical psychology
researchProduct

Evidence, and replication thereof, that molecular-genetic and environmental risks for psychosis impact through an affective pathway

2022

AbstractBackgroundThere is evidence that environmental and genetic risk factors for schizophrenia spectrum disorders are transdiagnostic and mediated in part through a generic pathway of affective dysregulation.MethodsWe analysed to what degree the impact of schizophrenia polygenic risk (PRS-SZ) and childhood adversity (CA) on psychosis outcomes was contingent on co-presence of affective dysregulation, defined as significant depressive symptoms, in (i) NEMESIS-2 (n = 6646), a representative general population sample, interviewed four times over nine years and (ii) EUGEI (n = 4068) a sample of patients with schizophrenia spectrum disorder, the siblings of these patients and controls.ResultsT…

RiskMultifactorial InheritancePsychosisHallucinationsAffective pathwayCLINICAL PSYCHOSISNEGATIVE SYMPTOMSDelusions03 medical and health sciences0302 clinical medicineMENTAL-HEALTH SURVEYchildhood adversityAffective dysregulationHumansMedicinegeneticspsychosisGenetic riskApplied Psychology1ST EPISODE PSYCHOSISGENERAL-POPULATIONbusiness.industryPSYCHIATRIC-DISORDERSSHORT-FORMAbsolute risk reductionNETWORK APPROACHIdeationmedicine.diseaseCHILDHOOD TRAUMA030227 psychiatryPsychiatry and Mental healthPsychotic DisordersSchizophreniaSchizophreniaSCHIZOPHRENIA SPECTRUM DISORDERSPolygenic risk scorebusinessenvironment030217 neurology & neurosurgerySchizophrenia spectrumClinical psychologyPsychological Medicine
researchProduct

Examining facial emotion recognition as an intermediate phenotype for psychosis: Findings from the EUGEI study

2022

The EUGEI project was supported by the European Community’s Seventh Framework Program under grant agreement No. HEALTH-F2- 2009-241909 (Project EU-GEI). Dr. Arango was supported by the Spanish Ministry of Science and Innovation; Instituto de Salud Carlos III (SAM16-PE07CP1, PI16/02012, PI19/024); CIBERSAM (...)

AdultMalePsychosisGENETIC RISKInterviews as Topic03 medical and health sciencesSTRUCTURED INTERVIEW0302 clinical medicinePolygenic risk scoreRisk FactorsSocial cognitionIMPUTATIONmedicineHumansPOLYGENIC RISKEmotion recognitionAssociation (psychology)Biological PsychiatryEmotionPharmacologyIntermediate phenotypebusiness.industrySiblingsUNAFFECTED SIBLINGSRegression analysisASSOCIATIONGenomicsmedicine.diseaseSocial cognition030227 psychiatrySchizotypal traitsINDIVIDUALSPolygenic risk scoresPhenotypePsychotic DisordersSchizophreniaRELIABILITYStructured interviewSchizophreniaFemalebusinessFacial Recognition030217 neurology & neurosurgeryClinical psychologyProgress in Neuro-Psychopharmacology and Biological Psychiatry
researchProduct

Examining the association between exposome score for schizophrenia and functioning in schizophrenia, siblings, and healthy controls: results from the…

2021

European Community's Seventh Framework Program, European Commission [HEALTH-F2-2009-241909]; Scientific and Technological Research Council of Turkey, 2219 International Postdoctoral Research Fellowship Program; Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (SAM16PE07CP1, PI16/02012, and PI19/024)...

cannabisPsychosisExposomeSYMPTOMSGlobal Assessment of Functioning1ST EPISODEGENETIC RISKVALIDATIONfunctioning03 medical and health sciences0302 clinical medicineCovariatemedicineHumanspsychosisPsiquiatriaPOPULATIONchildhood traumabiologybusiness.industryGLOBAL ASSESSMENTSiblingsRegression analysisEnvironmental exposuremedicine.diseasebiology.organism_classification3. Good health030227 psychiatryPsychiatry and Mental healthExposomeCross-Sectional StudiesPsychotic DisordersSchizophreniaRELIABILITYSchizophreniaCannabisCANNABIS USE DISORDERSbusinessenvironment030217 neurology & neurosurgeryClinical psychologyResearch Article
researchProduct